Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PDL BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
PDL BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
PDL BioPharma Acquires Remaining 50% Stake in Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 11
Noden Pharma Acquires Rights to Tekturna and Tekturna HCT from Novartis 12
PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 13
PDL BioPharma Acquires Royalty Revenue of Iclusig from ARIAD Pharma for USD200 Million 15
PDL BioPharma Acquires 75% of Royalty Interest in Cerdelga from University of Michigan for USD65.6 Million 17
PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 18
Licensing Agreements 20
Lee’s Pharma Enters into Licensing Agreement with Noden Pharma 20
PDL BioPharma Enters into Royalty Agreement with AxoGen 21
Equity Offering 22
Noden Pharma Raises USD75 Million in First Tranche of Private Placement of Shares 22
Debt Offering 23
PDL BioPharma Completes Public Offering of 2.75% Convertible Senior Notes due 2021 for USD150 Million 23
PDL BioPharma Completes Public Offering Of Notes Due 2018 For US$300 Million 24
Durata Therapeutics Completes First Tranche Of Private Placement Of Debt Securities For US$25 Million 26
PDL BioPharma Inc – Key Competitors 27
PDL BioPharma Inc – Key Employees 28
PDL BioPharma Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Nov 06, 2018: PDL BioPharma reports third quarter 2018 financial results 30
Aug 08, 2018: PDL BioPharma reports second quarter 2018 financial results 32
May 09, 2018: PDL BioPharma Announces First Quarter 2018 Financial Results 34
Mar 08, 2018: PDL BioPharma Announces Fourth Quarter and Year End 2017 Financial Results 35
Nov 02, 2017: PDL BioPharma Announces Third Quarter 2017 Financial Results 37
Aug 03, 2017: PDL BioPharma Announces Second Quarter 2017 Financial Results 40
May 03, 2017: PDL BioPharma Announces First Quarter 2017 Financial Results 42
Mar 01, 2017: PDL BioPharma Announces Fourth Quarter and Year End 2016 Financial Results 44
Corporate Communications 46
Jun 22, 2018: Elizabeth O’Farrell Named to PDL BioPharma’s Board of Directors 46
Jun 11, 2018: PDL BioPharma Appoints Shlomo Yanai As Board Director 47
Sep 11, 2017: PDL BioPharma Appoints Dominique Monnet as President 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PDL BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PDL BioPharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8
PDL BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
PDL BioPharma Acquires Remaining 50% Stake in Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 11
Noden Pharma Acquires Rights to Tekturna and Tekturna HCT from Novartis 12
PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 13
PDL BioPharma Acquires Royalty Revenue of Iclusig from ARIAD Pharma for USD200 Million 15
PDL BioPharma Acquires 75% of Royalty Interest in Cerdelga from University of Michigan for USD65.6 Million 17
PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 18
Lee's Pharma Enters into Licensing Agreement with Noden Pharma 20
PDL BioPharma Enters into Royalty Agreement with AxoGen 21
Noden Pharma Raises USD75 Million in First Tranche of Private Placement of Shares 22
PDL BioPharma Completes Public Offering of 2.75% Convertible Senior Notes due 2021 for USD150 Million 23
PDL BioPharma Completes Public Offering Of Notes Due 2018 For US$300 Million 24
Durata Therapeutics Completes First Tranche Of Private Placement Of Debt Securities For US$25 Million 26
PDL BioPharma Inc, Key Competitors 27
PDL BioPharma Inc, Key Employees 28
PDL BioPharma Inc, Subsidiaries 29
List of Figures
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
PDL BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
【免責事項】
http://www.globalresearch.jp/disclaimer